Increased Arf6-GTP elevates Nox4 through Erk1/2 in Ang II-treated human podocyte.

Abstract

Human podocytes were treated with 1 μM of angiotensin II (Ang II) for 24 h in the absence or presence of 10 μM of secinH3 (SH3). A. The levels of Nox4 were evaluated and compared. Data are presented as mean ± SD. n = 3. *p .01 vs. CTL, #p .05 vs. Ang II. B. Indirect immunofluorescence staining was performed for Nox4 (green color). The secondary antibody Alexa 488-conjugated goat anti-rabbit antibody alone was used for the blank control (A488 only). Magnification x 20. C. The activation level of Erk1/2 was assessed using immunoblot assay. Data are presented as mean ± SD. n = 3. *p .01 vs. 0 h. D. Human podocytes were pretreated for 1 h with the Erk1/2 inhibitor LY3214996 (1 μM; LY), and then Ang II was added at the final concentration of 1 μM and incubated for 24 h in the presence of 1 μM of LY3214996. The protein levels of Nox4 were evaluated. Data are presented as mean ± SD. n = 3. *p .01 vs. AngII-0min, #p S4 Fig.</p